Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Lunsumio
Pharma
EU signs off on Regeneron's T-cell engager for 2 blood cancers
Five months after the FDA rejected Regeneron’s bid for approval of odronextamab, the European Union has signed off on the treatment.
Kevin Dunleavy
Aug 26, 2024 10:35am
AbbVie's Epkinly follows Roche's Lunsumio into FL
Jun 27, 2024 10:21am
JPM24: Roche touts its rebound in hematology, led by Hemlibra
Jan 9, 2024 4:26pm
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
Dec 11, 2023 7:00am
With Polivy beat, Roche fleshes out blood cancer ambitions
Oct 19, 2023 11:28am
AbbVie, Genmab's Epkinly shows promise in follicular lymphoma
Jun 28, 2023 3:08pm
